Patients Stopping Anti-Obesity Medications Gain Back Weight Four Times Faster Compared to Dieters

A recent study indicates that individuals who discontinue blockbuster weight-loss injections like semaglutide or tirzepatide can put back on shed pounds far faster than those who halt conventional diet and exercise programs.

Published data in a prominent medical journal demonstrates that while overweight individuals can lose about a fifth of their total mass while on the medication, the weight returns at an estimated rate of nearly a kilo each month once they quit.

"Users buying such drugs need to be informed of the risk of rapid rebound weight gain when the medication concludes," warns researcher Dr. Susan Jebb.

Such speed of recovery means a return to original weight in about one and a half years.

Analyzing Therapies

The study, which looked at dozens of trials involving thousands of patients, compared the effects of GLP-1 agonists with other pills.

Scientists note that people who shed pounds through lifestyle changes alone typically experience a more gradual weight regain—around 0.1 kg a month—once they finish.

Explaining the Quick Regain

Doctors propose the mode of action of the drugs is key to understanding the heightened regain.

The injections copy a natural hormone called GLP-1, which helps regulate hunger.

"Sustained high doses of GLP-1 concentrations far above than the body's typical production might result in the body to produce less of its own natural GLP-1, and may also diminish responsiveness to its effects," said Dr. Adam Collins, a dietetics specialist.

"Discontinuation of this hormone supplement results in hunger is unsuppressed, making binge eating much more probable."

A Chronic Disease?

The NHS recommend the injections for individuals with obesity-related medical conditions, accompanied by prescribed lifestyle changes.

A number of clinicians contend that, considering the high risk of relapse, the therapy might need to be ongoing.

This perspective is reinforced by pharmaceutical companies, who state that the results "underscore the chronic nature of excess weight," similar to managing conditions like diabetes.

User Accounts

People who have come off the jabs report a powerful resurgence of cravings.

"It was like a switch that goes on and I was suddenly starving," said one woman.

This challenge is exacerbated if users have not established permanent dietary or behavioural modifications during therapy.

Growing Adoption

Survey data indicate that millions of people in the UK have tried these injections in the past year, with demand continuing to grow.

• Use is greater among females than males.
• The middle-aged age group shows the greatest level of interest.
• A large proportion obtain the medications through private prescriptions rather than public health services.

Finally, researchers caution that while GLP-1 drugs are potent tools for weight loss, they are not a magic cure and maintained weight loss hinges on integrated behavioural management.